In patients with AF and a bioprosthetic mitral valve, rivaroxaban was noninferior to warfarin for time to clinical events

Ying X. Gue; Professor Gregory Lip

doi:10.7326/acpj202104200-043

Back

In patients with AF and a bioprosthetic mitral valve, rivaroxaban was noninferior to warfarin for time to clinical events

Letter 2021 en

Abstract

1 min read

Guimarães HP, Lopes RD, de Barros E Silva PG, et al. <b>Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve.</b> N Engl J Med. 2020;383:2117-26. 33196155.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Editorial Material2023

Use of Direct-Acting Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Liver Disease

Theresa Hydes, Professor Gregory Lip, Deirdre A. Lane

Letter2020

In patients with no indication for anticoagulation after TAVR, rivaroxaban increased adverse events vs antiplatelets

Wern Yew Ding, Mark Field, Professor Gregory Lip

Letter2022

Atrial Cardiopathy and Cardioembolic Stroke

Darae Ko, Emelia Benjamin

Letter2020

Prevalence of Risk of Thrombosis and of Bleeding and Antithrombotic Treatment in Patients with Heart Failure

Massimo Pozzoli, José González‐Costello, Antoni Bayés‐Genís, Gianfranco Sinagra, Stefan D. Anker, Andrew J.S. Coats, María G. Crespo‐Leiro, Gerasimos Filippatos, Cécile Laroche, Aldo Maggioni, Alexandre Mebazaa, Massimo Piepoli, Luigi Tavazzi

Article2009

Lenalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma; Dosing of Lenalidomide According to Renal Function and Effect On Renal Impairment.

Meletios A Dimopoulos, Dimitrios Christoulas, Μαρία Ρούσσου, Efstathios Kastritis, Magdalini Migkou, Maria Gavriatopoulou, Μαρία Γκοτζαμανίδου, Marina Iakovaki, Charis Matsouka, Despina Mparmparoussi, Erasmia Psimenou, Irini Grapsa, Eleni Efstathiou, Evangelos Terpos